The goal of this proposal is to develop a novel approach how to ablate tumor cells, while leaving healthy cells alive. This approach is based on 123I, a radioactive iodine isotope that emits Auger electrons. Auger electrons have the advantage of dissipating their energy in a very narrow radius, principally confined to only 10 nanometers. They therefore inflict cellular damage only at their targeted site, which is in stark contrast to other forms of radioactive emission. We intend to target the DNA of cancer cells by conjugating 123I to inhibitors of the DNA repair enzyme PARP1. These inhibitors have shown to accumulate in the nuclei of cancer cells, and we have demonstrated that they are particularly useful for the delivery of targeted payloads to brain tumors. Auger emitting PARP1 targeted radiopharmaceuticals are less likely to damage kidney and liver than ?- or ?- emitting radionuclides, because in those organs, the overwhelming amount of activity should be retained outside of the nucleus, where the toxicity of Auger emitters is significantly lower. The ultimate goal of this study is to validate PARP1 targeted shuttles for Auger emitters in mouse models of glioblastoma. We envision that Auger emitters can be used to ablate tumor tissues, while at the same time toxicity to excretory organs can be kept to a minimum. All experiments will be performed at the Department of Radiology of Memorial Sloan-Kettering Cancer. For this application, an interdisciplinary team of experts has been brought together to aid in the translation of this technology. The research team will include Dr. Thomas Reiner (Radiochemistry and Imaging Sciences), Dr. Wolfgang Weber (Nuclear Medicine), Dr. Mitat G?nen (Biostatistics) and Dr. John Humm (Medical Physics). Together, they form an ideal team to pursue this novel research avenue, bringing together expertise from a wide variety of disciplines.
The specific aims of this proposal are to first synthesize a small library of 123I-labeled PARP1 targeted inhibitors and evaluate them as potential radiotherapeutic drugs. We will select the most successful candidates based on their binding characteristics, solubility and serum stability. Pharmacokinetic and -dynamic data will be obtained for all compounds, and the radiation dose to the tumors and normal organs determined. The lead PARP1 inhibitor (123I-iPARP1) with the most suitable pharmacokinetic profile (based on tumor uptake, in vitro efficacy, off-target accumulation, blood and tissue clearance) will be identified. It will be used o assess the therapeutic potential of radioiodine-labeled PARP1 inhibitors in mouse models of glioblastoma. We will perform a dose escalation study in xenograft as well as orthotopic models, administering 123I-iPARP1, both systemically as well as locally, and measure the effects on tumor growth and systemic toxicity. If successful, the generated data will form the foundation for a R01 application involving the same research team. We envision to study the lead 123I-iPARP1 construct in infiltrative mouse models of glioblastoma, and ultimately performing clinical trials at MSKCC.
This project uses a radioactive iodine isotope that emits Auger Electrons, which is a form of radioactive decay that is confined to very small spaces. By attaching the iodine isotope to a drug that binds to a DNA repair enzyme, we believe that we can shuttle it right next to the DNA of cancer cells, which will therefore be damaged and killed. During excretion, the isotope will not be near to the DNA of healthy cells, which is why we think that this therapeutic approach will have less side effects than current therapies and thus improve current cancer care.
| Roberts, Sheryl; Andreou, Chrysafis; Choi, Crystal et al. (2018) Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Chem Sci 9:5646-5657 |
| Carney, Brandon; Kossatz, Susanne; Lok, Benjamin H et al. (2018) Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nat Commun 9:176 |
| Jannetti, Stephen A; Carlucci, Giuseppe; Carney, Brandon et al. (2018) PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma. J Nucl Med 59:1225-1233 |
| Carlucci, Giuseppe; Carney, Brandon; Sadique, Ahmad et al. (2017) Evaluation of [18F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer. Nucl Med Biol 48:9-15 |
| Büchel, Gabriel E; Kossatz, Susanne; Sadique, Ahmad et al. (2017) cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339. Dalton Trans 46:11925-11941 |
| Kossatz, Susanne; Weber, Wolfgang; Reiner, Thomas (2017) Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent. Mol Imaging 16:1536012117723786 |
| Tang, Jun; Salloum, Darin; Carney, Brandon et al. (2017) Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 114:E7441-E7449 |
| Kossatz, Susanne; Carney, Brandon; Schweitzer, Melanie et al. (2017) Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. Cancer Res 77:2112-2123 |
| Büchel, Gabriel E; Carney, Brandon; Tang, Jun et al. (2017) A Novel Technique for Generating and Observing Chemiluminescence in a Biological Setting. J Vis Exp : |
| Büchel, Gabriel E; Carney, Brandon; Shaffer, Travis M et al. (2016) Near-Infrared Intraoperative Chemiluminescence Imaging. ChemMedChem 11:1978-82 |
